Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 2/20 | 0.49 |
| ▸ | DAO | P14920 | 1/20 | 0.48 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30523915 | 1.00 | PDE2A (0.49) | PDE2ADAOMRGPRX4ALDH1A1GAA | |
| SCHEMBL92949 | 0.84 | PDE2A (0.44) | PDE2AALDH1A1FFAR4IDO1HTR2A | |
| SCHEMBL81697 | 0.82 | DAO (0.50) | PDE2ADAOMRGPRX4ALDH1A1GAA | |
| SCHEMBL3211500 | 0.82 | DAO (0.49) | PDE2ADAOMRGPRX4ALDH1A1MAPT | |
| SCHEMBL1014987 | 0.81 | KLF10 (0.44) | PDE2AALDH1A1KDM4EFFAR4IDO1 | |
| SCHEMBL31085526 | 0.81 | KLF10 (0.44) | PDE2AALDH1A1KDM4EFFAR4IDO1 | |
| SCHEMBL3208015 | 0.80 | PDE2A (0.49) | PDE2ADAOMRGPRX4ALDH1A1MAPT | |
| SCHEMBL963581 | 0.80 | DAO (0.48) | PDE2ADAOMRGPRX4ALDH1A1MAPT | |
| SCHEMBL15684775 | 0.80 | DAO (0.48) | PDE2ADAOMRGPRX4ALDH1A1MAPT | |
| SCHEMBL2669965 | 0.80 | DAO (0.51) | PDE2ADAOMRGPRX4LMNAIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116555080-A | Preparation method of hybrid ester compound containing oxazole ring | 上海交通大学医学院附属仁济医院 | 2023-08-08 | — | — | CN | claimed |
| CN-116710431-A | Small molecule compounds and compositions | 泰洛治疗公司 | 2023-09-05 | — | — | CN | disclosed |
| CN-116555080-A | Preparation method of hybrid ester compound containing oxazole ring | 上海交通大学医学院附属仁济医院 | 2023-08-08 | — | — | CN | disclosed |
| EP-3270926-B1 | TRIAZOLYL PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME (US) | 2021-08-04 | — | — | EP | disclosed |
| US-10358435-B2 | Triazolyl pyrimidinone compounds as PDE2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-07-23 | — | — | US | disclosed |
| US-20180237422-A1 | TRIAZOLYL PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-08-23 | — | — | US | disclosed |
| EP-3270926-A1 | TRIAZOLYL PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2018-01-24 | — | — | EP | disclosed |
| EP-2838891-B1 | AROMATIC RING COMPOUND AS GHRELIN O-ACYLTRANSFERASE INHIBITOR | TAKEDA PHARMACEUTICALS CO (JP) | 2017-08-02 | — | — | EP | disclosed |
| WO-2016149058-A1 | TRIAZOLYL PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-09-22 | — | — | WO | disclosed |
| US-9238639-B2 | Aromatic ring compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-01-19 | — | — | US | disclosed |
| US-20100041892-A1 | Therapeutic agent for diabetes | ABE HIDENORI | 2010-02-18 | — | — | US | disclosed |
| US-20090270631-A1 | Therapeutic agent for diabetes | ABE HIDENORI | 2009-10-29 | — | — | US | disclosed |
| CN-101282725-A | Therapeutic agent for diabetes | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2008-10-08 | — | — | CN | disclosed |
| EP-1912645-A2 | THERAPEUTIC AGENT FOR DIABETES | Takeda Pharmaceutical Company Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
| US-20080051418-A1 | Arylalkanoic Acid Derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-02-28 | — | — | US | disclosed |
| US-20080009530-A1 | Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-10 | — | — | US | disclosed |
| EP-1829863-A1 | ARYLALKANOIC ACID DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2007-09-05 | — | — | EP | disclosed |
| WO-2007018314-A2 | THERAPEUTIC AGENT FOR DIABETES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-15 | — | — | WO | disclosed |
| US-6420409-B1 | GLUCOSE TOLERANCE, DIABETES,INSULIN RESISTANCE, POLYCYSTIC OVARY SYNDROME, HYPERLIPIDEMIA, ATHEROSCLEROSIS, CARDIOVASCULAR DISORDERS, HYPERGLYCEMIA, HYPERTENSION, STENOCARDIA, PULMONARY HYPERTENSION, CONGESTIVE HEART FAILURE, | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-07-16 | — | — | US | disclosed |
| EP-1020452-A1 | BENZIMIDAZOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270631-A1 | Therapeutic agent for diabetes | FABP4, SLC5A1, SLC5A2 | PDE2A 260/4885DAO 720/4885MRGPRX4 1727/4885 |
| US-20180237422-A1 | TRIAZOLYL PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | PDE2A, PDE12, PDE4D | PDE2A 1/4885DAO 772/4885MRGPRX4 3131/4885 |
| US-10358435-B2 | Triazolyl pyrimidinone compounds as PDE2 inhibitors | PDE2A, PDE12, PDE4D | PDE2A 1/4885DAO 772/4885MRGPRX4 3131/4885 |
| US-20080051418-A1 | Arylalkanoic Acid Derivative | INSR, NPY1R, GPR119 | PDE2A 4406/4885DAO 267/4885MRGPRX4 826/4885 |
| US-20080009530-A1 | Therapeutic Agent for Diabetes | FABP4, SLC5A1, SLC5A2 | PDE2A 390/4885DAO 727/4885MRGPRX4 1455/4885 |
| US-20100041892-A1 | Therapeutic agent for diabetes | FABP4, SLC5A1, SLC5A2 | PDE2A 260/4885DAO 720/4885MRGPRX4 1727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.